Multi‐centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope
Open Access
- 20 August 2009
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 11 (9), 881-886
- https://doi.org/10.1093/eurjhf/hfp106
Abstract
Aims The objective of this study is to report on our 5‐year collective experience on the use of perhexiline in the UK, in patients with chronic heart failure (CHF) and/or refractory angina with respect to ‘real‐life’ drug side effects and toxicity, therapeutic drug level monitoring, 5 year mortality outcomes and predictors of response to perhexiline therapy. Methods and results Data on clinical history, perhexiline monitoring, follow‐up, and mortality were retrospectively collated from centralized perhexiline databases from two tertiary referral centres. A total of 151 patients were on perhexiline therapy at two UK tertiary referral centres. At 3–4 months, 68.8% of patients had drug level within the therapeutic range and 20.8% were above the therapeutic range. A total of 58.9% of patients reported to have felt better on the perhexiline (responders). The presence of refractory angina was an independent predictor of response to perhexiline therapy (odds ratio 2.84, 95% confidence interval 1.28–6.32, P = 0.01). Five‐year mortality was non‐significantly different between patients with refractory angina, CHF, or both (20.5, 31.0, and 38.4%, P = 0.20, respectively). Conclusion Perhexiline therapy provides symptomatic relief in the majority of patients with minimal side effects or toxicity. Careful therapeutic level monitoring for dose titration is important to prevent acute and chronic toxicity. Patients with refractory angina were more likely to be responders.Keywords
This publication has 21 references indexed in Scilit:
- Metabolic Mechanisms in Heart FailureCirculation, 2007
- A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart FailureJournal of the American College of Cardiology, 2006
- Is the Failing Heart Energy Starved?Circulation Research, 2004
- Heart FailureThe New England Journal of Medicine, 2003
- Is perhexiline essential for the optimal management of angina pectoris?Australian and New Zealand Journal of Medicine, 1995
- Direct Evidence That Perhexiline Modifies Myocardial Substrate Utilization from Fatty Acids to LactateJournal of Cardiovascular Pharmacology, 1995
- Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.JCI Insight, 1993
- The medical treatment of angina pectoris.Heart, 1987
- Perhexiline maleate treatment for severe angina pectoris — correlations with pharmacokineticsInternational Journal of Cardiology, 1986
- Impaired oxidation of debrisoquine in patients with perhexiline liver injury.Gut, 1984